Efficacy, Safety and Cost Effectiveness of Metronomic Low Dose Versus Intermittent High Dose Capecitabine in Metastatic Breast Cancer
DOI:
https://doi.org/10.3889/oamjms.2021.7089Keywords:
Capecitabine, Metastatic breast cancer, Metronomic chemotherapyAbstract
AIM: The aim of the study is to compare the toxicity and cost-effectiveness between metronomic and intermittent capecitabine as maintenance therapy in female patients with metastatic breast cancer.
PATIENTS AND METHODS: All metastatic breast cancer patients with HER2 negative were included. The whole study population received six cycles of Docetaxel/Capecitabine then patients were randomized to either continuous (650 mg/m2 twice daily continuous) or intermittent Capecitabine (1000 mg/m2 twice daily every 21 days) as maintenance.
RESULTS: The study included 51 patients, 26 in the metronomic arm and 25 in the continuous. The median number of maintenance cycles, as well as the partial response, was higher in the continuous (18 vs. 13 cycles, p: 0.031; p: 0.038). The continuous arm was tolerable with significant less Grade 3 and 4 toxicity regarding nausea, vomiting, hand and foot syndrome, neutropenia, and elevated liver enzymes. (p: 0.03, 0.045, 0.051, 0.048, 0.06, respectively). On multivariate analysis, only patients receiving treatment as first-line had a better clinical response (p: 0.03) especially in the triple-negative group (p: 0.07). The metronomic therapy was more cost-effective with a 35.9% reduction of cost. ($ 746 vs. $1164). The progression-free survival and overall survival were not significant between the two groups.
CONCLUSION: Metronomic continuous capecitabine proved to be less toxic and more cost-effective.Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Grilli R, Chiesa V. Overuse in cancer care: Do European studies provide information useful to support policies? Health Res Policy Syst. 2018;16(1):12. https://doi.org/10.1186/s12961-018-0287-z PMid:29458403 DOI: https://doi.org/10.1186/s12961-018-0287-z
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. https://doi.org/10.3322/caac.21492 PMid:30207593 DOI: https://doi.org/10.3322/caac.21492
Surmeli ZG, Varol U, Cakar B, Degirmenci M, Arslan C, Piskin GD, et al. Capecitabine maintenance therapy following docetaxel/capecitabine combination treatment in patients with metastatic breast cancer. Oncol Lett. 2015;10(4):2598-602. https://doi.org/10.3892/ol.2015.3546 PMid:26622896 DOI: https://doi.org/10.3892/ol.2015.3546
Liu Y, Gu F, Liang J, Dai X, Wan C, Hong X, et al. The efficacy and toxicity profile of metronomic chemotherapy for metastatic breast cancer: A meta-analysis. PLoS One. 2017;12(3):e0173693. https://doi.org/10.1371/journal.pone.0173693 PMid:28296916 DOI: https://doi.org/10.1371/journal.pone.0173693
Ozdemir N, Aksoy S, Sendur MA, Akinci MB, Yazici O, Budakoglu B, et al. Capecitabine/cisplatin doublet in anthracycline and taxane pretreated and HER-2 negative metastatic breast carcinoma patients. J BUON. 2013;18(4):831-7. PMid:24344005
Stockler MR, Harvey VJ, Francis PA, Byrne MJ, Ackland SP, Fitzharris B, et al. Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer. J Clin Oncol. 2011;29(34):4498-504. https://doi.org/10.1016/j.breastdis.2012.06.030 PMid:22025143 DOI: https://doi.org/10.1200/JCO.2010.33.9101
Chen Y, Zhang J, Hu XC, Wang BY, Wang ZH, Wang LP, et al. Maintenance chemotherapy is effective in patients with metastatic triple negative breast cancer after first-line platinum-based chemotherapy. Ann Palliat Med. 2020;9(5):3018-27. https://doi.org/10.1093/annonc/mdz242.058 PMid:32787354 DOI: https://doi.org/10.21037/apm-20-578
Cazzaniga ME, Cortesi L, Ferzi A, Scaltriti L, Cicchiello F, Ciccarese M, et al. Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: Is it a way to optimize disease control? Final results of the VICTOR-2 study. Breast Cancer Res Treat. 2016;160(3):501-9. https://doi.org/10.1007/s10549-016-4009-3 PMid:27752847 DOI: https://doi.org/10.1007/s10549-016-4009-3
Abdallah H, Abourawash AS, Elgazzar M, Helal A. PCN124- cost effectiveness analysis of exemestane versus capecitabine monotherapy for patients with hormone receptor-positive and her2-negative, metastatic breast cancer from national cancer institute prespective in Egypt. Value Health. 2017;20(9):A434. https://doi.org/10.1016/j.jval.2017.08.207 DOI: https://doi.org/10.1016/j.jval.2017.08.207
Downloads
Published
How to Cite
License
Copyright (c) 2020 Hala Elsebaie, Wael Samir Makar Yassa, Shaimaa Lasheen, Noha IbrahimIbrahim (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
